Bioventus (BVS) Asset Writedowns and Impairment (2020 - 2026)

Bioventus has reported Asset Writedowns and Impairment for 7 years, with the latest figure at $230000.0 in Q1 2026.

• For the quarter ending Q1 2026, Asset Writedowns and Impairment fell 64.62% year-over-year to $230000.0; the trailing twelve-month figure through Mar 2026 stood at -$420000.0 (down 100.59% YoY), and the FY2024 full-year result was $36.4 million, down 53.75% from the prior year.
• Asset Writedowns and Impairment for Q1 2026 stood at $230000.0, up from -$843000.0 in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $124.7 million in Q4 2022, with the low at -$976000.0 in Q1 2024.
• Historically, Asset Writedowns and Impairment has averaged $18.7 million across 5 years, with a median of $1.1 million in 2023.
• Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment surged 56323.98% — and 2024, when it tumbled 190.45%.
• Bioventus' Asset Writedowns and Impairment stood at $10.3 million in 2022, then sank by 89.51% to $1.1 million in 2023, then jumped by 3326.32% to $37.0 million in 2024, then tumbled by 102.28% to -$843000.0 in 2025, then soared by 127.28% to $230000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $230000.0 (Q1 2026), -$843000.0 (Q3 2025), and $193000.0 (Q2 2025), per Business Quant data.